ArticleBMC pregnancy and childbirth2026
The effectiveness of 100 mg aspirin in preventing superimposed preeclampsia in women with chronic hypertension: a real-world study.
Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveThis study aims to evaluate the real-world effectiveness of 100 mg aspirin in preventing superimposed preeclampsia (PE) in pregnant women with chronic hypertension (CHTN). STUDY
designThis retrospective cohort study included pregnant women with CHTN who began prenatal care before 20 weeks of gestation and delivered a singleton at Nanjing Drum Tower Hospital, affiliated with Nanjing University Medical School. The deliveries occurred between January 1, 2018, and May 1, 2025. The primary exposure was 100 mg/day aspirin initiated between 12 and 20 weeks of gestation, and the primary outcome was the incidence of superimposed PE. Secondary outcomes included PE delivery before 34 weeks, PE delivery before 37 weeks, preterm birth, postpartum hemorrhage, gestational diabetes mellitus, small for gestational age (SGA), and a composite of adverse neonatal outcomes. Multivariable logistic regression and inverse probability of treatment weighting (IPTW) were used to adjust for confounding factors.
resultsDuring the study period, 367 women met the inclusion criteria, with 111 in the aspirin group and 256 in the control group. After IPTW adjustment, baseline characteristics were comparable between the two groups. The incidence of superimposed PE was 34.6% in the aspirin group and 37.7% in the control group, with no statistically significant difference (weighted OR = 0.87, 95% CI: 0.49-1.54; p >0.05). In secondary outcomes, the incidence of SGA was significantly lower in the aspirin group both before and after IPTW adjustment (p<0.05); however, no significant differences were observed for other outcomes (p>0.05). Additionally, subgroup analyses showed no significant heterogeneity in aspirin effect when stratified by aspirin-related factors (initiation timing, adherence, and concurrent calcium supplementation) or CHTN-related factors (timing of diagnosis, blood pressure levels before 20 weeks of gestation, and use of antihypertensive medication within three months prior to conception or before 20 weeks) (p >0.05).
conclusionOur study suggests that initiating 100 mg/day of aspirin between 12 and 20 weeks of gestation does not significantly reduce superimposed PE in women with CHTN; however, it significantly reduces the risk of SGA. Subgroup analyses also indicated that even initiation before 16 weeks did not provide additional preventive effect against PE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.